Study reveals impact of dramatic increase in
commercially available biosimilars and progress in the areas of
patient accessibility and treatment affordability
DUBLIN,
Ohio, Feb. 29, 2024 /PRNewswire/ -- Today,
Cardinal Health (NYSE: CAH) released its 2024 Biosimilars
Report: insights on a pivotal year of evolution and
expansion, an analysis of key recent economic,
competitive, legislative and societal developments in biosimilars.
The publication highlights legislative developments and new
treatments, including adalimumab biosimilars. The report also
provides the perspectives of retina specialists on biosimilars,
ahead of the expected launch of multiple new biosimilars for
retinal diseases.
"It is more important than ever that all stakeholders of
the healthcare ecosystem understand the significant benefits
biosimilars offer to patients, providers, practices and payers
alike," said Fran Gregory, PharmD,
MBA, VP, Cardinal Health Emerging Therapies. "The savings generated
by biosimilars will play an increasingly important part in creating
a balance between funding innovative new treatments and reducing
the overall financial burden on the healthcare system. This report
offers critical context on this rapidly changing clinical and
market landscape, and the role biosimilars will play in increasing
the accessibility and affordability of care."
The report examines a year of major developments in biosimilars,
offering expert commentary and provider perspectives on a rapidly
changing industry landscape. Featuring new research derived from
surveys and expert interviews, the report offers new insights into
market growth, drivers of biosimilar adoption and remaining
barriers to widespread uptake.
With 2024 expected to be a critical year for retina
biosimilars, Cardinal Health surveyed providers in ophthalmology to
obtain perspectives that may influence adoption while highlighting
continued obstacles to wider use of biosimilars. Nearly 80% of
survey participants said they are "extremely" or "very" familiar
with biosimilars, though fewer than 60% have prescribed a
biosimilar for the treatment of a retinal disorder. 82% of retina
specialists said they would be "very" or "somewhat" more likely to
prescribe biosimilars if they became a payer's preferred drug.
Notably, the research also suggests widespread belief in
biosimilars' potential impact on healthcare system sustainability,
with 75% of participants agreeing that biosimilars can improve
healthcare system sustainability.
In addition to this new research, the report also includes
in-depth analysis of:
- The evolving payer landscape
- Emerging best practices for managing biosimilar inventory
- How biosimilars are promoting access and healthcare system
sustainability
- The biosimilars product pipeline
The report can be accessed at
www.cardinalhealth.com/biosimilarsreport
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global
manufacturer and distributor of medical and laboratory products,
and a provider of performance and data solutions for healthcare
facilities. With more than 50 years in business, operations in more
than 30 countries and approximately 48,000 employees globally,
Cardinal Health is essential to care. Information about Cardinal
Health is available at cardinalhealth.com.
Media contact: Tori Simmons,
Victoria.Simmons@cardinalhealth.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cardinal-health-annual-research-report-examines-milestone-year-in-biosimilars-302075391.html
SOURCE Cardinal Health